Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune... see more

TSX:ONC - Post Discussion

Oncolytics Biotech Inc > Both Roche and Incyte have turned me down as an MSL
View:
Post by Noteable on Jul 28, 2023 6:40pm

Both Roche and Incyte have turned me down as an MSL

Go figure !
Comment by fox7mf on Jul 28, 2023 8:16pm
I just read on renaissancecapital.com that yesterday Adlai Nortye filed with the SEC a US IPO for $115m.
Comment by itntdf on Jul 28, 2023 10:09pm
this taken from the sec filing: Other programs AN1004 Pelareorep, or AN1004, is an intravenously delivered oncolytic virus. We own the exclusive rights to AN1004 in China, Singapore, and South Korea through an in-licensing agreement with Oncolytics Biotech, Inc. Ongoing Phase Ib clinical trial of AN1004 in combination with atezolizumab and gemcitabine/nab-paclitaxel demonstrated encouraging ...more  
Comment by westcoast1000 on Jul 29, 2023 10:52am
Thanks for this useful comment, ITNTDF. It shows pela has not fallen out of favor with AN. This FUD has been spread by many posters here and elsewhere.
Comment by fox7mf on Jul 29, 2023 11:53am
Maybe Adlai is maneuvering to take a run at owning Oncy outright. They say they want to be a leader in the next wave of immuno oncology and Pela is just that. They'd need backing to pull off such a huge acquisition tho...perhaps Japan's Takeda? 
Comment by fox7mf on Jul 29, 2023 11:57am
Adlai and a partnering foreign BP could put a $25b deal together for Oncy and the FTC would not be able to say squat about it;)
Comment by jimsenior on Jul 29, 2023 1:39pm
A closer look at AN. Two drugs appear to be at their forefront. Buparlisib  -  AN2025.  Palupiprant -  AN0025. AN2025 has been in 90 trials or more. AN2025 and AN0025 and Tecentriq are involved in an interesting Double/Triple that is progressing very nicely. NCT04975958. Fair to assume a strong connection to Roche. AN0025 and Keytruda are being tested together. So a ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities